![schrodinger company schrodinger company](https://www.schrodinger.com/sites/default/files/styles/large_square/public/schrodinger-acc.jpg)
As of spring 2019 the ACC inhibitor was moving through late-stage clinical trials in NASH. In 2016, Nimbus Therapeutics sold an Acetyl-CoA carboxylase (ACC) inhibitor designed by Schrödinger to Gilead in a deal worth up to $1.2 billion. Nimbus Therapeutics, co-founded by Schrödinger, uses Schrödinger's drug screening and design platform for drug discovery. Schrödinger's partners include larger pharmaceutical companies, including Bayer, Takeda, Sanofi.
SCHRODINGER COMPANY SOFTWARE
In addition to its computational platforms Schrödinger provides professional services, including custom software development and training, computer-cluster design and implementation, and research-based drug discovery projects. Schrödinger's products include molecular modeling programs, and an Enterprise Informatics Platform named LiveDesign, an enterprise application designed to facilitate communication among interdisciplinary research teams. Schrödinger's computational platforms evaluate compounds in silico, with experimental accuracy on properties such as binding affinity and solubility.